52179-26-7 Usage
Uses
Used in Pharmaceutical Industry:
P-(2,2-DICHLOROCYCLOPROPYL)PHENOL is used as an impurity in the production of ciprofibrate for its role in [application reason]. Ciprofibrate, a hypolipemic agent, is structurally related to clofibrate and is utilized to regulate lipid levels in the body, thus contributing to the management of various lipid-related health conditions.
As an impurity in the pharmaceutical compound ciprofibrate, P-(2,2-DICHLOROCYCLOPROPYL)PHENOL may also be subject to regulatory controls and quality assurance measures to ensure the safety and efficacy of the final drug product. The presence of this impurity in ciprofibrate could potentially influence the drug's pharmacological properties, side effects, or overall therapeutic outcomes, making it an important consideration in the development and production of hypolipemic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 52179-26-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,1,7 and 9 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 52179-26:
(7*5)+(6*2)+(5*1)+(4*7)+(3*9)+(2*2)+(1*6)=117
117 % 10 = 7
So 52179-26-7 is a valid CAS Registry Number.
52179-26-7Relevant academic research and scientific papers
Levo-ciprofibrate
-
, (2008/06/13)
Levo-ciprofibrate or a pharmaceutically acceptable salt thereof is disclosed.
Dextro-ciprofibrate
-
, (2008/06/13)
Dextro-ciprofibrate or a pharmaceutically acceptable salt thereof is disclosed.
Halocyclopropyl substituted phenoxyalkanoic acids
-
, (2008/06/13)
Halocyclopropyl substituted phenoxyalkanoic acids and esters thereof, having hypocholesteremic activity are prepared via several alternative synthetic approaches, involving as the key reactions interaction of a substituted phenylalkene with a carbene source to introduce the halocyclopropyl moiety, and reaction of a substituted phenol with chloroform and a lower-alkanone in the presence of base, or with a lower-alkyl α-bromo-alkanoate, to form the phenoxyalkanoic acid moiety.
